Literature DB >> 23642634

A clinically useful social anxiety disorder outcome scale.

Kristy Dalrymple1, Jennifer Martinez, Elizabeth Tepe, Diane Young, Iwona Chelminski, Theresa Morgan, Mark Zimmerman.   

Abstract

Increasingly, emphasis is being placed on measurement-based care to improve the quality of treatment. Although much of the focus has been on depression, measurement-based care may be particularly applicable to social anxiety disorder (SAD) given its high prevalence, high comorbidity with other disorders, and association with significant functional impairment. Many self-report scales for SAD currently exist, but these scales possess limitations related to length and/or accessibility that may serve as barriers to their use in monitoring outcome in routine clinical practice. Therefore, the aim of the current study was to develop and validate the Clinically Useful Social Anxiety Disorder Outcome Scale (CUSADOS), a self-report measure of SAD. The CUSADOS was designed to be reliable, valid, sensitive to change, brief, easy to score, and easily accessible, to facilitate its use in routine clinical settings. The psychometric properties of the CUSADOS were examined in 2415 psychiatric outpatients who were presenting for treatment and had completed a semi-structured diagnostic interview. The CUSADOS demonstrated excellent internal consistency, and high item-total correlations and test-retest reliability. Within a sub-sample of 381 patients, the CUSADOS possessed good discriminant and convergent validity as it was more highly correlated with other measures of SAD than with other psychiatric disorders. Furthermore, scores were higher in outpatients with a current diagnosis of SAD compared to those without a SAD diagnosis. Preliminary support also was obtained for the sensitivity to change of the CUSADOS in a sample of 15 outpatients receiving treatment for comorbid SAD and depression. Results from this validation study in a large psychiatric sample show that the CUSADOS possesses good psychometric properties. Its brevity and ease of scoring also suggest that it is feasible to incorporate into routine clinical practice.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23642634      PMCID: PMC3740001          DOI: 10.1016/j.comppsych.2013.02.006

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  43 in total

1.  Psychiatrists in the UK do not use outcomes measures. National survey.

Authors:  Simon M Gilbody; Allan O House; Trevor A Sheldon
Journal:  Br J Psychiatry       Date:  2002-02       Impact factor: 9.319

2.  Development and validation of the Penn State Worry Questionnaire.

Authors:  T J Meyer; M L Miller; R L Metzger; T D Borkovec
Journal:  Behav Res Ther       Date:  1990

3.  Mini-SPIN: A brief screening assessment for generalized social anxiety disorder.

Authors:  K M Connor; K A Kobak; L E Churchill; D Katzelnick; J R Davidson
Journal:  Depress Anxiety       Date:  2001       Impact factor: 6.505

4.  Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry.

Authors:  J K Hsiao; J J Bartko; W Z Potter
Journal:  Arch Gen Psychiatry       Date:  1989-07

5.  Barriers to the treatment of social anxiety.

Authors:  M Olfson; M Guardino; E Struening; F R Schneier; F Hellman; D F Klein
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

6.  Developing a screening index for community studies of somatization disorder.

Authors:  M Swartz; D Hughes; L George; D Blazer; R Landerman; K Bucholz
Journal:  J Psychiatr Res       Date:  1986       Impact factor: 4.791

7.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

8.  Social phobia.

Authors:  M R Liebowitz
Journal:  Mod Probl Pharmacopsychiatry       Date:  1987

9.  Impact of generalized social anxiety disorder in managed care.

Authors:  D J Katzelnick; K A Kobak; T DeLeire; H J Henk; J H Greist; J R Davidson; F R Schneier; M B Stein; C P Helstad
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

10.  Age of onset of social anxiety disorder in depressed outpatients.

Authors:  Kristy L Dalrymple; Mark Zimmerman
Journal:  J Anxiety Disord       Date:  2010-08-19
View more
  5 in total

Review 1.  A Review of Scales to Measure Social Anxiety Disorder in Clinical and Epidemiological Studies.

Authors:  Quincy J J Wong; Bree Gregory; Lauren F McLellan
Journal:  Curr Psychiatry Rep       Date:  2016-04       Impact factor: 5.285

2.  A detailed hierarchical model of psychopathology: From individual symptoms up to the general factor of psychopathology.

Authors:  Miriam K Forbes; Matthew Sunderland; Ronald M Rapee; Philip J Batterham; Alison L Calear; Natacha Carragher; Camilo Ruggero; Mark Zimmerman; Andrew J Baillie; Samantha J Lynch; Louise Mewton; Tim Slade; Robert F Krueger
Journal:  Clin Psychol Sci       Date:  2021-02-19

3.  Reconsidering the associations between self-reported alcohol use disorder and mental health problems in the light of co-occurring addictions in young Swiss men.

Authors:  Simon Marmet; Joseph Studer; Mélissa Lemoine; Véronique S Grazioli; Nicolas Bertholet; Gerhard Gmel
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

4.  Problematic smartphone use in young Swiss men: Its association with problematic substance use and risk factors derived from the pathway model.

Authors:  Michelle Dey; Joseph Studer; Michael Patrick Schaub; Gerhard Gmel; David Daniel Ebert; Jenny Yi-Chen Lee; Severin Haug
Journal:  J Behav Addict       Date:  2019-05-13       Impact factor: 6.756

5.  Unique versus shared associations between self-reported behavioral addictions and substance use disorders and mental health problems: A commonality analysis in a large sample of young Swiss men.

Authors:  Simon Marmet; Joseph Studer; Matthias Wicki; Nicolas Bertholet; Yasser Khazaal; Gerhard Gmel
Journal:  J Behav Addict       Date:  2019-12-01       Impact factor: 6.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.